17-allylamino-17-demethoxygeldanamycin; COOH terminus of Hsp70-interacting protein; sodium reabsorption; nephron; proteasome HYPERTENSION IS THE MOST COMMON disease in the human population, affecting over one billion individuals worldwide, and one of the major risk factors in cardiovascular diseases including stroke, myocardial infarction, and heart and kidney failure. The pathogenesis of this disease is largely unknown, but high salt intake has been proposed as a major cause for high blood pressure (31) . In this context, the kidney (in concert with other organs such as the gastrointestinal tract) plays a major role to tightly regulate Na ϩ and fluid homeostasis. A primary regulator is aldosterone, which mediates its hormonal effects through a nuclear receptor, the mineralocorticoid receptor (MR or NR3C2) (2, 54) , which belongs to the steroid/thyroid hormone receptor superfamily including glucocorticoid receptor (GR), thyroid receptors A and B, retinoic acid receptor, vitamin D receptor, and other orphan receptors. The importance of the MR in Na ϩ balance and blood pressure control has been demonstrated by either loss-of-function mutations in the gene encoding MR, causing autosomal dominant pseudohypoaldosteronism type 1 (18) , or gain-of-function mutations leading to a severe inherited form of early-onset hypertension, which is exacerbated during pregnancy (17) . The expression of the MR is wide, from epithelial tissues, most notably in the kidney and colon, where it controls water and electrolyte balance (39) , to nonepithelial cells, such as adipocytes, myocytes, endothelial cells, and others (55) . The human MR structure includes three functional domains, namely 1) an aminoterminal domain of 602 amino acids, being mainly involved in the regulation of MR-mediated transcription, 2) a central zinc-finger DNAbinding domain of 66 amino acids, recognizing the specific response element on MR target gene promoters, and 3) a carboxyterminal ligand-binding domain of 251 amino acids, allowing selective hormone binding (55) . Within the steroid receptor superfamily, MR is the only receptor that binds under physiological condition two classes of hormones, namely the mineralocorticoids (aldosterone and deoxycorticosterone) and the glucocorticoids (cortisol or corticosterone). Given that the plasmatic concentration of free cortisol is 1,000-fold higher than that of aldosterone, in aldosterone-sensitive epithelia in the colon or the distal nephron, the MR is coexpressed with 11␤-hydroxysteroid dehydrogenase type 2, which metabolizes cortisol into an inactive metabolite to prevent overactivation of MR signaling (12, 51) . In its nonactivated state, MR is predominantly cytoplasmic and part of a large heteromeric complex interacting with a number of proteins. Among these, the chaperone protein heat shock protein 90 (Hsp90) is the one that is best characterized. Chaperone proteins play an important role in the conversion of misfolded proteins to a functional conformation. In the case of MR/Hsp90, their association is crucial for proper ligand binding and receptor function. Indeed, previously it was shown that disruption of this interaction by geldanamycin, a benzoquinone ansamycin agent, leads to decreased MR-mediated transcription of a transfected luciferase reporter gene (3) . A number of other proteins are known to interact with MR in its basal state, such as Hsp70, p23, p48, FK-binding protein 59 immunophilins, or cyclophillin 40 (6, 42, 55) ; they are thought to play a critical role for maintaining the MR in an appropriate conformation and for ligand-dependant activation. Upon activation, these interactions are disrupted and the cytoplasmic complex is dissociated, allowing the translocation of MR into the nucleus, where it binds transcriptional cofactors to regulate transcription of target genes.
Different approaches to pharmacological inhibition of aldosterone signaling are being intensely studied as treatment options for chronic kidney disease with the goal of delaying the progression of kidney damage (36) . Moreover, treatment with either selective (eplerenone) or nonselective (spironolactone) aldosterone antagonists diminishes the risk of cardiovascular death and hospitalization in patients with congestive heart failure (40, 41) . Aldosterone antagonists are also known to have antihypertensive effects (29) . Pharmacological destabilization of MR protein represents an additional approach to inhibiting aldosterone signaling. Thus understanding the mechanisms that govern MR stability is crucial, and several previous studies investigated the fate of cytoplasmic unliganded MR/GR and its partner during the basal state (4, 6, 28, 57) . Previously it was shown that geldanamycin inhibits the ATP cycle of Hsp90 and prevents the maturation of substrate proteins (27, 58) . Whitesell and Cook (58) have demonstrated that the exposure to geldanamycin induces degradation of the GR. Bamberger et al. (3) confirmed that geldanamycin inhibits both MR-and GR-induced transcription of a luciferase reporter gene in nonepithelial cells, but they did not observe any decrease of GR expression. One limitation of these studies is that the rather severe hepatotoxicity of the drug prevented the study of the pharmacological effect on MR function in vivo. In vitro and animal studies have shown that the activity of geldanamycin analog 17-allylamino-17-demethoxygeldanamycin (17-AAG) is similar to geldanamycin but considerably less hepatotoxic. Even though Hsp90 affinity to 17-AAG is lower than geldanamycin, both gave the same biological effects at similar concentrations (47) .
In this study, we assessed the effects of 17-AAG on MR function in vitro and in vivo. We found that 17-AAG increased the association between MR and the ubiquitin-protein ligase, COOH terminus of Hsp70-interacting protein (CHIP), leading to decrease in MR stability in vitro and in vivo. The consequence of this receptor destabilization was inhibition of MRinduced transcription and, consequently, Na ϩ reabsorption by renal epithelial cells.
MATERIALS AND METHODS
Cells culture and transfection. Mouse cortical collecting duct clone 1 (mCCD cl1) cells (15) were used between passages 10 and 23. Cells were cultured in complete medium containing DMEM-F12 medium (1:1), 5 g/ml insulin, 5 g/ml transferrin, 6 ϫ 10 Ϫ8 M sodium selenate, 5 ϫ 10 Ϫ8 M dexamethasone, 1 nM triiodothyronine, 10 ng/ml epidermal growth factor, 10 mM HEPES, pH 7.4, and 2% FCS. For experiments, cells were grown on Transwell filters coated with collagen, cultured the first 5 days in complete medium, and then for 5 more days in medium containing DMEM-F12 medium (1:1), 5 g/ml insulin, 6 ϫ 10 Ϫ8 M sodium selenate, 3 ϫ 10 Ϫ9 M dexamethasone, 1 nM triiodothyronine, and 10 mM HEPES, pH 7,4. Before the experiments, cells were incubated overnight in minimal medium [DMEM-F12 (1:1) and 10 mM HEPES, pH 7.4] and then treated or not with 3 mM or 300 nM aldosterone for 4 h. Collagen was prepared as previously described (15) . The cortical collecting duct cells M1 and M1/tetracyclin-ON (Tet-ON)/MR (33) were cultured in medium containing DMEM-F12 and 5% FCS. These cells were transfected with Lipofectamine following the manufacturer's protocol (Invitrogen). The MR expression in M1/Tet-ON/MR cells was allowed by a 48-h doxycycline treatment (500 ng/ml) (33 Immunoblotting and immunoprecipitation. Cell extracts were prepared in lysis buffer containing 50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EGTA, pH 8.0, 10% glycerol, 1% Triton X-100, 1.2 mg/ml NEM, and complete protease inhibitor cocktail (1 tablet/.20 ml; Roche). Before use 1 mM DTT, 100 mM sodium fluoride, and 10 mM disodium pyrophosphate were added to the lysis buffer. After centrifugation for 20 min at 20,000 g and 4°C, supernatants were collected and assayed for total protein. For immunoprecipitation, 200-g proteins were incubated overnight at 4°C under rotation with the antibody directed against MR or Myc for CHIP. Immunoprecipitates were then incubated with protein G-Sepharose beads (Amersham) at 4°C for 1 h. Beads were washed three times with 1 ml of wash buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 1 mM EGTA, 10% glycerol, 0.2% Triton X-100, 1.5 mM MgCl 2, and 1 mM PMSF) and resuspended in 50 l of 2ϫ sample buffer. Samples of eluted immunoprecipitates were submitted to 8% SDS-PAGE and transferred onto nitrocellulose membrane (GE Healthcare Hybond-ECL).
Immunofluorescence analysis. M1 cells were cotransfected with MR and CHIP as described above. Forty-eight hours after transfection cells were treated or not with aldosterone (300 nM) for 2 h. Afterward, cells were fixed in 4% formaldehyde for 30 min and permeabilized in 0.1% Triton X-100. Then cells were incubated with the primary antibody overnight at 4°C followed by the secondary antibody conjugated to Texas Red or FITC for 1 h at room temperature. The cover slips were mounted by the mounting medium (Dako) and viewed on a fluorescence microscope.
Subcellular fractionation. M1 cells were removed from the plate and pelleted at 300 g. The cell pellet was resuspended in lysis buffer containing 25 mM HEPES, pH 7.4, 1 mM PMSF, 1 mM EDTA, 10 mM leupeptin, 10 g/ml aprotinin, 2 g/ml pepstatin, and 0.08% ␤-mercaptoethanol. The cells were homogenized in a tight-fitting Dounce homogenizer, and nuclei were pelleted by a 30-min centrifugation at 3,000 g. After being washed in lysis buffer, nuclei were resuspended in SDS lysis buffer. The samples were analyzed by anti-MR antibodies, and the purity of the fractions was monitored by immunoblot analysis with anti-lamin B and anti-␣-tubulin.
Transcriptional reporter assay. M1 cells were seeded in 24-well plates and then cotransfected by Lipofectamine with the reporter gene MMTV-luc (provided by P. Fuller), the constitutive luciferase vector coding for Renilla, and the indicated plasmids. After 30 h, cells were exposed to aldosterone (100 nM) with or without 17-AAG (1 M) for 16 h. During the aldosterone treatment, cells were cotreated with the GR-specific inhibitor RU486 (10 M), allowing us to measure only the MR-induced activity. After hormone treatment, cells were washed twice with PBS and lysed with 100 l of passive lysis buffer (Promega). Luciferase activity was determined by using a luciferase kit (Promega). Luciferase activity was normalized for constitutive Renilla luciferase (RLU). Data are given as means in fold induction ϭ firefly RLUinduced/firefly RLUnoninduced and expressed Ϯ SE of a triplicate experiment.
Quantitative real-time PCR. Total RNA was extracted from mCCDcl1 cells with Trizol (Invitrogen) according to the manufacturer's instructions, and reverse transcription was carried out using SuperScript II reverse transcriptase (Invitrogen). Quantitative real-time PCR analysis of Sgk1 was done on an ABI 7500 sequence detector (Applied Biosystems). The primers were obtained from Applied Biosystems (corresponding to the following order numbers: Sgk1, Mm00441380_m1). The reactions were done according to the manufacturer's instructions; each reaction was done in triplicate. The data were analyzed using the software provided with the instrument, and results were normalized to GAPDH and to the control condition.
Membrane potential and resistance measurements. Confluent mCCDcl1 cells were seeded and grown on collagen-coated Transwell filters for measuring the Na ϩ transport response to aldosterone. Transepithelial potential difference (in mV) and transepithelial electrical resistance (Ohm/cm 2 ) were recorded under sterile condition using Millicell-ERS ohmmeter apparatus (Millipore), and the corresponding currents were calculated. In each experiment, there were three filters per condition. Before measuring, cells were treated or not for 4 h with aldosterone (3 nM or 300 nM), with or without 17-AAG (1 M).
Animal experiments. Eight adult female C57BL/6 mice were divided into two groups, one group as vehicle control and the other one treated with 17-AAG (LC Laboratories). The protocols for animal experimentation were approved by an independent governmental Swiss review committee.The drug was dissolved in 10% DMSO and physiological buffer (116.35 mM NaCl, 12.44 mM NaHPO 4, 3.16 mM KH2PO4). During the experiment, 17-AAG was injected daily intraperitoneally at a dose of 40 mg/kg body wt during 3 days. After 3 days of drug or vehicle treatment, the animals were euthanized with carbon dioxide and kidneys were collected. For tissue protein extraction, the kidneys were homogenized by ultrasound in extraction solution (250 mM sucrose, 150 mM NaCl, 30 mM Tris·HCl pH 7.5) and complete protease inhibitor cocktail (1 tablet/.20 ml; Roche). Before use 1 mM DTT, 100 mM sodium fluoride, and 10 mM disodium pyrophosphate were added to the extraction solution. After centrifugation for 15 min at 1,500 g and 4°C, supernatants were collected and assayed for total protein.
RESULTS

17-AAG decreased MR protein expression and aldosteroneinduced modification.
To assess the effect of the geldanamycin analog 17-AAG on MR, we examined in the mCCD cl1 a well-characterized cell model that responds to physiological concentrations of aldosterone (15), whether or not 17-AAG treatment influences its expression. We treated these cells with increasing doses of 17-AAG (0.1 M to 2.0 M) for 4 h. 17-AAG induced a decrease of endogenous MR protein expression in a dose-dependant manner (Fig. 1A) . This observation was confirmed in M1/Tet-ON/MR cells that express MR in a doxycycline-dependent manner (33) . As shown in Fig. 1B , the expression of the doxycycline-induced MR was strongly decreased after a 4-h-long treatment with 1 M 17-AAG. Several aldosterone-induced posttranslational MR modifications have been described previously on MR, such as phosphorylation (1, 30, 32) , acetylation (14, 55) , or sumoylation (52). When we treated kidney epithelial cells with aldosterone, we observed an increase of the apparent molecular weight of both the endogenous and transfected MR characterized by a shift of ϳ30 kDa on Western blots (Fig. 1, B-D) . This aldosterone-induced shift may be specific for renal epithelial cells because it was almost undetectable in nondifferentiated cells such as human embryonic kidney-293 cells (data not shown). Interestingly, 17-AAG not only promoted a decrease of MR expression but also interfered with the aldosteroneinduced shift (Fig. 1B) . To further confirm the effect of 17-AAG on the shift of MR, we treated M1/Tet-ON/MR cells at different lengths of time with aldosterone (Fig. 1C) . We observed that the MR shift appears within minutes after aldosterone exposure, consistent with an early nongenomic effect of aldosterone on MR (13, 30) . Furthermore, cotreatment by aldosterone and 17-AAG not only decreased MR expression but also delayed the aldosterone-induced shift (Fig. 1C) . As shown in Fig. 1D , the aldosterone-induced shift is not only time but also dose dependent (Fig. 1D) . To confirm that this shift was ligand dependent, we simultaneously treated M1/Tet-ON/MR cells with aldosterone and its antagonist spironolactone. We found that spironolactone totally blocked the aldosterone-induced shift of MR, suggesting that the binding of aldosterone to its receptor was crucial for MR modification (Fig. 1E) .
17-AAG reduces MR stability via the ubiquitin proteasome pathway. Given that disruption of Hsp90 heterocomplexes by 17-AAG leads to the degradation of Hsp90 substrates by the proteasome (5) and given that MR can be polyubiquitylated (a proteasomal degradation signal) (53), we postulated that the effect of 17-AAG is blocked by proteasome inhibitors such as MG-132. Indeed, as shown in Fig. 2A, 6 h of MG-132 treatment completely abolished the 17-AAG-induced decrease of MR expression in M1/Tet-ON/MR cells ( Fig. 2A) . Furthermore, the proteasome inhibitor also prevented the aldosterone-induced shift, consistent with previous observations showing that an active proteasome is essential for MR-mediated transcriptional activation (53) . Next, we determined the effect of 17-AAG on endogenous MR half-life. The protein synthesis inhibitor cycloheximide (CHX) was added to mCCD cl1 cells to block de novo protein synthesis. Remaining levels of MR in the cells at different time points after CHX treatment were monitored by Western blotting (Fig. 2B, top) . The half-life of endogenous MR was estimated to be around 12 h in basal condition (Fig. 2B, bottom) . In contrast, the addition of 17-AAG dramatically decreased the level of MR expression in the cell and decreased the receptor half-life to 0.6 h (Fig.  2B, bottom) . To provide further evidence for a 17-AAGinduced proteasomal degradation of MR, we examined the polyubiquitylation level of MR in the presence or absence of 17-AAG (Fig. 2C) . We found that polyubiquitylated MR was not detected in basal condition, but addition of 17-AAG decreased the amount of MR in the cell and in parallel increased its polyubiquitylated forms. Then, to equalize the amount of MR between the 17-AAG treated and nontreated cells, we inhibited the proteasomal degradation by MG-132 (Fig. 2C) . Under these conditions, we found that polyubiquitylation of MR increased and that 17-AAG stimulated MR polyubiquitylation as well (Fig. 2C) .
CHIP is required for the 17-AAG-mediated MR degradation. The Hsp90 inhibitor 17-AAG blocks the ATP/ADP binding pocket of Hsp90 and keeps this chaperone protein in a nonactive form (23) . In several cases, the ubiquitin-protein ligase CHIP has been reported to be the pivotal enzyme involved in the degradation of Hsp90 client protein, including some nuclear receptors such as GR, estrogen receptor-␣, aryl hydrocarbon receptor, or androgen receptor (8, 11, 24, 34, 56) . Therefore, we assessed a possible regulatory role for CHIP in the 17-AAGmediated MR degradation. We cotransfected M1 cells with MR- and Myc-tagged CHIP. We found that overexpression of wildtype CHIP decreased MR protein level (Fig. 3A) . In parallel, two mutants of CHIP were cotransfected with MR, CHIP⌬Ubox lacking the COOH-terminal catalytic domain, or CHIP⌬TPR deleted of the NH 2 terminus containing the interaction domain with chaperone proteins. CHIP⌬Ubox completely lost its ability to decrease MR expression (Fig. 3A) , indicating that the ubiquitinprotein ligase activity of CHIP is needed for MR degradation.
Interestingly, CHIP⌬TPR had the same effect on MR suppression as wild-type CHIP (Fig. 3A) . We hypothesized that the mutant CHIP⌬TPR that conserved the homodimerization domain (aa 128 -229) could be recruited to MR via an endogenous CHIP. To investigate this hypothesis, we verified whether MR was able to interact with CHIP by coimmunoprecipitation experiments in M1 cells cotransfected with MR-and Myc-tagged CHIP (Fig. 3B) . We observed that, when both MR and Myc-CHIP were coex- Fig. 3 . COOH terminus of Hsp70-interacting protein (CHIP) requirement for MR degradation. A: M1 cells were cotransfected with hMR and CHIP wild-type (wt), CHIP⌬ tetratricopeptide repeat (TPR), or CHIP⌬Ubox. Cell lysates were subjected to immunoblotting using antibodies against MR, Myc, and actin as a loading control. The MR expression level was quantified, and values were normalized to actin and displayed as means Ϯ SE (n ϭ 3) **P Ͻ 0.01. B: M1 cells were cotransfected with hMR and CHIP wt. Cell lysates were immunoprecipitated with anti-MR and blotted with anti-Myc or immunoprecipitated with anti-Myc and blotted with anti-MR. The expression of proteins under investigation was determined by direct immunoblotting. C: M1 cells were cotransfected with MR and CHIP and treated with or without aldosterone (Aldo) (300 nM). Then cells were immunostained with anti-MR and anti-CHIP, and the localization of the two proteins was analyzed by a fluorescence microscope. The experiments in B and C have been repeated twice. D: mCCDcl1 cells were treated with or without 17-AAG (1 M) for 4 h, and cell lysates were immunoprecipitated with anti-MR and blotted with anti-CHIP and anti-MR for control. The expression of CHIP and MR was determined by direct immunoblotting. The level of interacted CHIP was quantified, and values were normalized to total CHIP in the lysate and the precipitated MR and displayed as means Ϯ SE (n ϭ 3), *P Ͻ 0.05. E: M1-siCHIP and M1-siControl were transfected with hMR and treated with or without 17-AAG (1 M) for 4 h before lysis. Cell lysates were subjected to immunoblotting using antibodies against MR, CHIP, and actin as a loading control. These data are representative of 3 experiments.
pressed, CHIP was detected in a complex immunoprecipitated with anti-MR antibody, and MR was present in a complex immunoprecipitated with anti-Myc antibody. Interestingly, MR was also able to interact with CHIP⌬Ubox and CHIP⌬TPR, suggesting that both CHIP mutants can be recruited to MR (Supplemental Fig. S1 ; supplemental material is available for this article online at the American Journal of Physiology Renal Physiology website).
Next, we performed immunofluorescence experiments to confirm the colocalization of CHIP and MR (Fig. 3C) . In basal state, MR and CHIP were localized predominantly in the cytoplasm. Aldosterone induced the translocation of the MR, but not CHIP, into the nucleus, indicating that CHIP preferentially interacts with the nonactivated cytosolic MR. To examine whether CHIP associates with MR under physiological conditions, we precipitated endogenous MR from mCCDcl1 cells treated or not with 17-AAG. We found that CHIP was present in the immunocomplex, and this association was increased about fivefold by 17-AAG treatment (Fig. 3D) . These results indicate that CHIP associates with MR in epithelial kidney cells, and this endogenous interaction is promoted by 17-AAG. We also observed that 17-AAG decreased the association between MR and Hsp90 that confirmed in kidney epithelial cells the previous observation of Galigniana and collaborators (16) and conversely increased the CHIP/Hsp90 interaction (Supplemental Fig. S2 ). Finally, to determine whether 17-AAG promotes its effects through the activity of CHIP, we established a stably transfected M1 cell line where endogenous CHIP expression was suppressed by shRNA (Fig.  3E) . As anticipated, CHIP depletion increased MR expression level, and abrogated 17-AAG mediated MR degradation, confirming that MR is a CHIP substrate and that 17-AAG induces the degradation of the receptor by recruiting the ubiquitinprotein ligase CHIP to the MR.
17-AAG decreases MR-mediated transcriptional activation.
As is typical for nuclear receptors, aldosterone treatment induces the translocation of the MR in the nucleus, where it can bind glucocorticoid response elements and regulate target genes (44) . When we exposed the cells to 17-AAG, we observed a reduction of the total pool of MR (Fig. 4A, left) .
Fig. 4. 17-AAG inhibits MR signaling transactivation.
A: M1 cells were transfected with MR and treated with or without aldosterone (300 nM) for 2 h. Total lysate and nuclear fractions were analyzed by immunoblotting with anti-MR. As controls, the fractions were reprobed for ␣-tubulin (cytoplasmic) and lamin B (nuclear). B: M1 cells were transfected with mouse mammary tumor virus (MMTV)-luc, CMV-Renilla, and hMR together with shCHIP or shControl. Twenty-four hours after transfection, cells were treated for 16 h by aldosterone (100 nM) or 17-AAG (1 M); then firefly luciferase (from MMTV-luc) and Renilla luciferase activity were measured. Fold induction ϭ firefly RLUinduced/ firefly RLUnoninduced, and all were normalized to Renilla (RLU). Data are given as means Ϯ SE of triplicates, *P Ͻ 0.05. C and D: mCCDcl1 cells grown on collagen-coated permeable filters were treated with or without 17-AAG (1 M), aldosterone (3 or 300 nM), or both for 4 h. C: abundance of glucocorticoid-inducible kinase (SGK)1 mRNA in mCCDcl1 cells was measured by quantitative RT-PCR. Given are means relative to GAPDH Ϯ SE (n ϭ 3). D: cell lysates were subjected to immunoblotting using antibodies against SGK1 and actin as a loading control (representative of 3 independent experiments).
Moreover, MR was not detectable in the nucleus after 17-AAG treatment, suggesting that 17-AAG prevented the translocation of the remaining pool of MR. The nonaccumulation of MR in the nucleus suggested that 17-AAG decreased the transcription of target genes. To verify this hypothesis, we examined whether 17-AAG treatment could influence MR transcription in CCD cells. We first tested the effect of 17-AAG on the aldosterone-responsive reporter gene mouse mammary tumor virus (MMTV)-luc (Fig. 4B) . Consistent with earlier published observations (3), 17-AAG treatment resulted in a significant decrease of aldosterone-dependent transcriptional activity. When CHIP was depleted by shCHIP, aldosterone induced transcription of MMTV-reporter gene despite treatment with 17-AAG. This suggests that 17-AAG inhibits aldosteroneinduced transactivation, and this inhibitory effect requires the presence of the CHIP E3 ligase. To investigate the significance of 17-AAG on an endogenous target of aldosterone stimulation in cortical collecting duct cells, we followed the synthesis of Sgk1 mRNA in mCCD cl1 cells by qRT-PCR assay. As anticipated, Sgk1 presented a significant upregulation on the mRNA level upon treatment with 300 nM of aldosterone, and this induction was drastically inhibited by 17-AAG (Fig. 4C) . Consequently, the endogenous SGK1 protein levels, which were increased at 3 nM or at 300 nM of aldosterone, were reversed by 17-AAG treatment (Fig. 4D) .
17-AAG interferes with the ability of aldosterone to increase sodium reabsorption by cortical collecting duct cells. To test the possible impact of 17-AAG on Na
ϩ reabsorption via the epithelial Na ϩ channel (ENaC), we determined the transepithelial current of polarized mCCD cl1 grown of collagen-coated semipermeable filters (15) . As shown in Fig. 5A , 17-AAG repressed in a dose-dependent manner the transepithelial current mediated by 300 nM aldosterone but did not affect the basal current. A dose of 1 M of 17-AAG was sufficient to completely reduce the current to the baseline. Furthermore, addition of 10 M amiloride fully inhibited both the baselineand the aldosterone-stimulated Na ϩ transport, confirming that the current reflected ENaC-mediated Na ϩ transport and 17-AAG limited this transport. Similarly, 3 nM aldosterone treatment induced a twofold increase of the Na ϩ current and slightly reduced the transepithelial resistance as expected (Fig.  5, C and B) . The addition of 1 M of 17-AAG had no effect on the basal current but completely abolished the aldosteroneinduced current (Fig. 5B ) and the diminution of transepithelial resistance (Fig. 5C) . The fact that the transepithelial resistance did not vary after 17-AAG treatment suggests that the drug did not perturb the function of tight junctions and that the observed variations were likely attributable to variations in the transepithelial transport of Na ϩ . Hence, these results suggest that 17-AAG inhibition of cellular MR expression and its transcriptional activity inhibit the Na ϩ transport by ENaC in kidney epithelial cells.
17-AAG decreases MR expression in vivo.
To examine the physiological relevance of our in vitro observations in vivo, we designed an experimental protocol according to previously published pharmacokinetics data (9, 10) . Adult female C57BL/6 mice were divided into two groups, one group treated with 17-AAG and the other as control. 17-AAG or vehicle was injected daily intraperitoneally for 3 days, at a dose of 40 mg/kg body wt. After 3 days, the animals were euthanized and kidneys were collected and assayed for total protein. As shown in Fig. 6A , the MR receptor was less expressed in the total kidney of treated mice than control mice. The quantification of the immunoblots indicated an ϳ60% decrease of MR expression in 17-AAG-treated mice (Fig.  6B) . As previously observed in vitro, 17-AAG also decreased the level of the low-affinity aldosterone receptor GR protein in the kidney (58) .
DISCUSSION
Here we report that the geldanamycin analog 17-AAG interferes in renal epithelial cells with MR function by inducing its polyubiquitylation by the E3 ubiquitin ligase CHIP and subsequent degradation by the proteasome. We also observe that 17-AAG inhibits aldosterone-dependent posttranslational modifications of the receptor and translocation into the nucleus. This leads to inhibition of transcriptional activation of a luciferase reporter gene, or the aldosterone-dependent target protein Sgk1, and consequently to blunting of the Na ϩ transport response of the cells.
Geldanamycin and its analogs are frequently used to disturb the function and expression of steroid and nuclear receptors (3, 11, 34, 58) . They bind with high affinity to the ATP binding pocket of Hsp90 and block the protein in its ADP-bound conformation, thereby promoting the degradation of Hsp90 client proteins (5, 49) . The finding that 17-AAG decreases endogenous MR expression and half-life by inducing its degradation via ubiquitin/proteasome pathway supports previous work by Tirard et al. (53) reporting that MR can be polyubiquitylated and the proteasome is involved in MR regulation. In the unliganded state, the MR is a part of a large protein complex, including Hsp90 and a number of other cochaperones and proteins, which prevents the nonspecific activation of the receptor. However, this complex also maintains the MR in an appropriate conformational state for ligand binding and activation. Once activated by aldosterone, the receptor is rapidly posttranslationally modified, leading to regulation of early nongenomic and late genomic responses (30, 55) . We found that, in epithelial cells, this MR posttranslational activation translates into an increase of the apparent molecular weight of the receptor, which to the best of our knowledge has not been reported before. This shift is not only blocked by spironolactone but also by 17-AAG (Fig. 1) . These data therefore tend to indicate that 17-AAG delays the aldosterone-induced shift of the MR, either indirectly by interfering with ligand binding or by blocking the effect of the ligand once it is bound to the receptor.
Upon aldosterone binding, MR translocates into the nucleus to regulate the transcription of numerous target genes. Similar to a recent study demonstrating that Hsp90 is involved in nuclear translocation of MR and geldanamycin impairs the steroid-dependent MR accumulation in the nucleus (16), we find that inhibition of MR activation by 17-AAG prevents the nuclear translocation of MR, as evidenced by the complete depletion of nuclear pool of the MR upon 17-AAG treatment. The consequence of the nonaccumulation of MR in the nucleus in presence of 17-AAG is an inhibition of aldosterone-induced transcription of target genes. This inhibition occurs even at high dose of aldosterone, which is known to activate not only MR but also the aldosterone low-affinity receptor GR, and is therefore concordant with the work of Bamberger et al. (3) , who demonstrated that geldanamycin inhibits the MR-and GR-regulated transcription. In summary, our data show that the inhibition of MR function by 17-AAG is attributable to both a decrease of the receptor expression and activation in kidney epithelial cells.
Several posttranslational modifications that regulate MR functions have been described (1, 14, 30, 32, 52, 55) . The identification of the target residues and the enzyme involved in these modifications remains lacking and warrants further investigation. In this context, no ubiquitin-protein ligase has been described to mediate polyubiquitylation of MR. We report in this work that it is CHIP that interacts with the MR, ubiquitylates it via its U-box catalytic domain, and decreases its expression and that these events are stimulated by 17-AAG. The cellular depletion of CHIP increases MR levels and abrogates MR degradation mediated by 17-AAG, showing that the ubiquitin-ligase CHIP is involved in MR turnover and 17-AAG-promoted degradation. These observations are similar to the GR, which is also a well-characterized CHIP substrate. Indeed, for this analogous receptor it was shown that CHIP reduces the steroid-binding activity and transactivation potential by inducing its ubiquitylation and degradation by the proteasome (8, 42, 58) . It is known that CHIP function is dependent on its interaction with the chaperone proteins Hsp70/90, which are involved in substrate recognition for CHIP (35) . In our experiments, we found that the catalytic domain of CHIP (U-box) is necessary for the CHIP effect on MR, whereas deletion of the TPR domain has no incidence on the MR degradation mediated by CHIP. Such TPR-independent degradation mechanism could be explained by the fact that CHIP could form a homodimer via a coiled-coil domain (aa 128 -229). This dimerization is essential for the activity of this E3-ligase (37) . The ⌬TPR mutant (aa 128 -303) used for our experiment possesses this dimerization domain and could be recruited for MR degradation via an endogenous CHIP. Furthermore, the effect of the ⌬TPR mutant on target protein degradation was already described for other CHIP substrates such as the transcription factor Runx1 or the DNA polymerase-␤ involved in the base excision repair in DNA lesions (38, 48) .
Numerous preclinical data and multiple phase I and II trials reported safety and promising in vitro activity of 17-AAG in cancer treatment (19, 22, 25, 45, 50) . Among the side effects of 17-AAG patient administration, cases of dyspnea, diarrhea, and fatigue were reported (25, 45) . These three pathophysiological effects of 17-AAG may be explained in part by a misregulation of ENaC. In the lung, Na ϩ transport via ENaC expressed in alveolar epithelial cells provides the driving force for fluid removal from the alveolar space. It is well documented that inhibition or decrease of ENaC activity in the lung causes troubles of alveolar fluid clearance and lung fluid balance that could induce neonate early death (26, 43) . In the colon, altered ENaC expression leads to impaired Na ϩ and water absorption that contributes to diarrhea (21, 59) . Finally, loss of function mutations in ENaC genes disturbs Na ϩ reabsorption by the kidney and causes pseudohypoaldosteronismtype 1, characterized by hypovolemia, hyperkalemia, metabolic acidosis, and hypotension (7) . Given these different postulates, we have confirmed that 17-AAG inhibits ENaCmediated Na ϩ reabsorption in renal epithelial cells mCCD cl1 . Furthermore, our in vivo study showed a significant decrease of MR in 17-AAG-treated mice, suggesting that this drug possesses a potential diuretic effect. During the experiment, we do not observe any physiological difference between the treated and nontreated mice, suggesting that the large remaining pool (40%) of MR after 17-AAG treatment may be sufficient to maintain solute balance. On the other hand, the absence of a Na ϩ challenge in the diet (i.e., low-salt diet) could melt down the differences between the control and the 17-AAG-treated group as well as an increase of the plasma aldosterone. This phenomenon was previously described in mutant mice where MR is partially impaired in the nephron (46) . These mutant mice do not express MR in the connecting tubule (CNT) and collecting duct; nevertheless they retain renal ENaC activity. The authors provided evidence that, coupled to an increase of blood aldosterone concentration, the remaining MR in a small segment composed of the late distal convoluted tubule and early CNT can compensate to a large extent deficient ENaC-mediated sodium reabsorption in the late CNT and collecting duct (46) .
In summary, our data show that disruption of Hsp90 activity leads to MR degradation. This degradation is due to the ubiquitin proteasome pathway and requires the presence of the CHIP ubiquitin-protein ligase. In view of the 17-AAG effect on Na ϩ reabsorption in mCCD cl1 cells and MR expression in vitro and in vivo, this drug provides a useful molecule for the development of therapeutics, not only in cancer treatment, but also for disrupting MR signaling and downstream responses. It may represent an alternative and distinct approach from conventional aldosterone antagonists.
